18 Years Advancing Biopharma R&D Innovation, Decision Making, and Operations

A CONFERENCE FOR BIOPHARMA EXECUTIVES AT THE INTERSECTION OF SCIENCE, BUSINESS, AND OPERATIONS

In a highly competitive and often uncertain drug development landscape, it is important for pharma, biotech, and device companies to continuously optimize their strategy, evaluate their portfolios, improve decision making, reduce risk, and effectively deploy resources. Cambridge Healthtech Institute and the BioPharma Strategy Series present Executive Decision Making 2020, 5 days of high-level content, interactive discussions and networking. This executive forum unites R&D executives from the biopharma community to share best practices in project and portfolio management, R&D innovation, decision analysis, forecasting, and resource management. Attendees will gain strategic insights and proven tools, methods, and perspectives from a variety of leaders at the intersection of science, business, and operations.



Featured Speakers



Cleat Jerden,

Executive Director, Business Performance, Business Analysis and External Process Development, Amgen

Daniel Patrick,

Global Group Leader, R&D Program Management Office and Portfolio Management, Daiichi Sankyo

Sean Gallagher, MS, MBA,

Associate Director of Capacity Management, Janssen R&D

Monika Przybyl,

Manager, Performance, Demand and Capacity, Regulatory Operations, GRA, GSK

Richard Bayney, PhD,

President & Founder, Project & Portfolio Value Creation (PPVC)




MEETINGS LIKE THESE ARE VERY HELPFUL FOR ADVANCING THE COLLECTIVE PRODUCTIVITY OF THE INDUSTRY, AND IN SO DOING, HELP EVERYONE BY ENABLING AND EXPEDITING THE DEVELOPMENT OF NEW MEDICINES FOR THE PATIENTS THAT NEED THEM.

- Vice President, WRD Business Operations, Pfizer, Inc.

Join us in the Heart of Philadelphia!

CONFERENCE VENUE: LE MERIDIEN PHILADELPHIA

Discounted Room Rate: $249 s/d

Discounted Room Rate Cut-off Date: September 28, 2020